You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDSUMMARY Arboviruses present a constant threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, primarily mosquitoes. One of them, Aedes aegypti, is the primary vector of several widely spread arboviruses such as Zika, dengue and West Nile viruses, and for most of them, human-licensed vaccines do not exist or are suboptimal. These pathogens are transmitted int ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirements
SBC: PASCALL Systems, Incorporated Topic: NIDAPROJECT SUMMARY In light of the opioid crises, minimizing postoperative pain and postoperative opioid requirements to reduce chronic opioid dependency among surgical patients have become major concerns for surgeons and anesthesiologists. Effective intraoperative nociception control can mitigate these concerns. Unfortunately, existing nociceptive monitoring tools use indicators that are inherently ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections
SBC: EXBAQ LLC Topic: NIAIDPROJECT SUMMARY/ABSTRACT Two million Healthcare Associated Infections (HAIs) occur per year in the US, killing andgt;90,000 patients and costing ~$50-100 billion (adjusted by CPI to 2020 dollars). HAIs are the 6th leading cause of death in the US, ahead of diabetes and kidney disease. Reducing HAIs is a top priority of the US Department of Health and Human Services1 and experts have called for nov ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Design and Engineering of Biodegradable 3D Nanoprinted Microcarriers for HIV Drug Delivery
SBC: INFRATRAC INC Topic: NIAIDPrecise, customizable drug delivery remains a long-term goal, for HIV in particular, as such technologies would allow therapies tailored to a patient’s biological makeup and potentially improve adherence. Extended-release methods address part of the issue, but face limitations. A novel drug delivery system could offer better pediatric dosing, via both oral and new routes of administration. Exist ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution
SBC: Fluid Discovery Inc Topic: 400Abstract The advance of biotechnology is dependent on approaches for rapidly iterating through genetically engineered enzymes and pathways. While computational and gene synthesis techniques have seen considerable innovation in the last few decades, screening variants for desired activities has lagged behind, with few notable advances. Indeed, microwell plates, a nearly 60-year-old technology, rema ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency
SBC: COURAGE THERAPEUTICS INC Topic: 102The melanocortin peptide therapeutic setmelanotide, (ImcivreeTM), is highly effective in the treatment of the rare obesity syndromes, POMC and leptin receptor deficiency. However, the drug is ineffective for the most common syndromic obesity, melanocortin-4 receptor (MC4R) deficiency (MC4R haploinsufficiency), found at a prevalence greater than 1/1000 individuals. Further, the drug is ineffective ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Broadly Accessible Technologies for Single-cell Joint Analysis of Transcriptome and Epigenome
SBC: EPIGENOME TECHNOLOGIES, INC Topic: 101AbstractHistone modifications carry rich information of cellular memory and gene regulatory mechanisms. Single cell analysis of histone modification in conjunction with transcriptome could recover this critical layer of cell identity and help to dissect the cellular and molecular composition of complex tissues such as the brain. We recently developed an ultra-high throughput single cell multi-omic ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of the UValidate platform for the profiling of topically applied chemical agents.
SBC: AMELIA TECHNOLOGIES LLC Topic: NIEHSProject Summary Skin is the first line of defense against the outside environment. When the skin barrier is breached by UV irradiation (UVR) or toxic chemicals, living cell layers including epidermal keratinocytes, melanocytes and dermal fibroblasts are subjected to DNA damage. If unrepaired, this damage can lead to photoaging and cutaneous carcinogenesis. In fact, skin cancer is by far the most c ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Smartphone App to Increase and Maintain Physical Activity in African American Men (FitBrothers)
SBC: KLEIN BUENDEL, INC. Topic: 102Physical activity (PA) is a modifiable risk factor for a number of preventable chronic diseases, including cardiovascular disease, strokes, obesity, and diabetes. These conditions constitute health disparities for African American men. Behavioral interventions have proven to be effective in promoting increases in physical activity. While behavior change programs have been shown to assist participa ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
An Efficacy Trial of a Digital Therapeutic for Suicide Prevention
SBC: Oui Therapeutics, LLC Topic: NIMHABSTRACT Suicide is one of the top ten causes of death in the US and suicide rates have increased steadily over the last twenty years. Currently, the most effective treatment options are cognitive behavioral therapies for suicide prevention (CBT-SP), which have been shown to reduce both suicide attempt (SA) risk and suicide ideation (SI). However, access to these treatments is limited because ther ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health